Results of a phase 2 study evaluating the safety and efficacy of an enhanced recovery after surgery (ERAS) clinical pathway in patients with early-stage gastric cancer showed that nearly 80% of patients were discharged on postoperative day 4. The findings from this study were published in the Journal of Surgical Oncology.1
the implementation of ERAS clinical pathways, designed to shorten postoperative
recovery time, has become more common in the setting of early-stage colorectal
cancer, the risks and benefits of such an approach in early-stage gastric
cancer have not been well established.
This single-arm, open-label study (ClinicalTrials.gov Identifier: NCT01642953) conducted at a single center in Korea prospectively enrolled 133 patients with early-stage gastric cancer scheduled to undergo subtotal gastrectomy using minimally invasive surgery followed by inclusion in an ERAS clinical pathway program.
management approaches characterizing this ERAS clinical pathway included early
ambulation, introduction of a liquid diet and a soft blended diet on
postoperative days 2 and 3, respectively, as well as hospital discharge on
postoperative day 4.
primary study endpoint was the ERAS clinical pathway completion rate, with
secondary study endpoints including 30-day rates of postoperative complications,
readmission, and mortality.
Want to read more?
Please login or register first to view this content.